Gal-3 blocks the binding between PD-1 and pembrolizumab.
Greisen SR, Bendix M, Nielsen MA, Pedersen K, Jensen NH, Hvid M, Mikkelsen JH, Drace T, Boesen T, Steiniche T, Schmidt H, Deleuran B.
Greisen SR, et al. Among authors: nielsen ma.
J Immunother Cancer. 2024 Oct 2;12(10):e009952. doi: 10.1136/jitc-2024-009952.
J Immunother Cancer. 2024.
PMID: 39357979
Free PMC article.